Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritisTsutomu Takeuchi, Takayoshi Koike, Yoshiya Tanaka et al.|Annals of the Rheumatic Diseases|2007Cited by 413
Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation studyVera Golder, Eric F. Morand, Rangi Kandane‐Rathnayake et al.|The Lancet Rheumatology|2019Cited by 161